**Shares of clinical-stage immune-oncology co Imugene
rise as much as 14.6% to A$0.055; biggest intraday pct gain since Sept. 2
** U.S. FDA gives orphan drug status to co's VAXINA treatment, aimed at treating cholangiocarcinoma, a form of bile tract cancer
** FDA grants orphan drug status to promote drug development for rare diseases affecting fewer than 200,000 people in the U.S.
** Co says orphan status gives it range of incentives including tax credits, potential grant funding and 7-year market exclusivity
** About 56.7 mln shares change hands vs 30-day avg volume of about 23.7 mln shares
**Stock down 54.5% YTD
(Reporting by Nikita Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。